The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico

BACKGROUND: In many patients, the risk of cardiovascular (CV) events persists despite statin treatment and attaining target LDL–c levels. This residual risk is in part attributed to atherogenic dyslipidemia (AD). We studied the clinical effectiveness of the CNIC-polypill in improving the lipid profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Álvarez, Enrique, Verdejo, Juan, Ocampo, Salvador, Ponte-Negretti, Carlos I., Ruíz, Emilio, Ríos, Marco Martínez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452496/
https://www.ncbi.nlm.nih.gov/pubmed/32885029
http://dx.doi.org/10.1016/j.ijcha.2020.100545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452496/
https://www.ncbi.nlm.nih.gov/pubmed/32885029
http://dx.doi.org/10.1016/j.ijcha.2020.100545

Ejemplares similares